Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. (Full text)

Prostate Cancer Care and Outcomes Study (PCOS).General health and disease specific quality of life were self-reported at seven time points over a 15 year period, using the 12-item Short Form Health Survey scale, University of California, Los Angeles prostate cancer index, and expanded prostate cancer index composite short form (EPIC-26). Adjusted mean differences were calculated with controls as the comparison group. Clinical significance of adjusted mean differences was assessed by the minimally (...) Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. To assess treatment related changes in quality of life up to 15 years after diagnosis of localised prostate cancer.Population based, prospective cohort study with follow-up over 15 years.New South Wales, Australia.1642 men with localised prostate cancer, aged less than 70, and 786 controls randomly recruited from the New South Wales electoral roll into the New South Wales

2020 BMJ PubMed abstract

2. Abiraterone for treating metastatic prostate cancer

diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT); metastatic castration-resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated; and metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. Subsidy status Generic (...) Abiraterone for treating metastatic prostate cancer '); } else { document.write(' '); } ACE | Abiraterone for treating metastatic prostate cancer Search > > Abiraterone for treating metastatic prostate cancer - Abiraterone for treating metastatic prostate cancer Published on 1 October 2020 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended: Generic abiraterone acetate 250 mg tablet (Abiranat) in line with its registered indications for treating: newly

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

3. Therapies for Clinically Localized Prostate Cancer

differences may be limited to men age 65 and older or those with intermediate-risk disease. Active monitoring using PSA-based monitoring probably results in little to no difference in all-cause or prostate cancer mortality compared with RP or EBR plus AD over 10 years. Metastases were infrequent, but AM probably results in a small increase compared with RP and EBR+AD. Effects may not vary by patient or tumor risk factors. Harms were lowest with AM compared with RP or EBR plus AD or AS versus photodynamic (...) cancer (CLPC) detected clinically rather than by prostate-specific antigen (PSA) screening, radical prostatectomy (RP) may reduce mortality and metastases more than watchful waiting (WW) but causes more harms. Mortality reductions may be limited to men age 65 and older and those with intermediate-risk disease. • Active monitoring (AM) probably results in little to no mortality difference versus RP or external beam radiation (EBR)+androgen deprivation (AD) in PSA-detected CLPC and may result in fewer

2020 Effective Health Care Program (AHRQ)

4. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. (Abstract)

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic review of randomised controlled trials (RCTs) comparing these radiotherapy (...) approaches.We used a prospective framework for adaptive meta-analysis (FAME), starting the review process while eligible trials were ongoing. RCTs were eligible if they aimed to compare immediate adjuvant radiotherapy versus early salvage radiotherapy, following radical prostatectomy in men (age ≥18 years) with intermediate-risk or high-risk, localised or locally advanced prostate cancer. We searched trial registers and conference proceedings until July 8, 2020, to identify eligible RCTs. By establishing

2020 Lancet

5. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. (Abstract)

) in cohort A, 0.83 (95% CI, 0.11 to 5.98) in cohort B, and 0.55 (95% CI, 0.29 to 1.06) in the overall population.Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent, those who were initially assigned to receive olaparib had a significantly longer duration of overall survival than those who were assigned to receive enzalutamide (...) Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final

2020 NEJM

6. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. (Abstract)

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at the time (...) . The incidence of adverse events after the start of treatment was similar in the two groups; no new safety signals were observed.Among men with nonmetastatic, castration-resistant prostate cancer, the percentage of patients who were alive at 3 years was significantly higher among those who received darolutamide than among those who received placebo. The incidence of adverse events was similar in the two groups. (Funded by Bayer HealthCare and Orion Pharma; ARAMIS ClinicalTrials.gov number, NCT02200614

2020 NEJM

7. Prostate Cancer Part 2: Follow-up in Primary Care

Treatment, Cancer Care Ontario, A Palliative Care Approach for Primary Care, HealthLinkBC – Advance Care Planning, Provincial Health Services Authority Trans Care BC – A Primary Care Toolkit – Gender-affirming Care for Trans, Two-spirit, and Gender Diverse Patients in BC, ​ ​ Diagnostic Code: 185 (malignant neoplasm of prostate) Abbreviations ACP - advance care plan ADT - androgen deprivation therapy AGREE - appraisal of guidelines for research and evaluation CBC - complete blood count CCO - Cancer Care (...) diagnosis onwards (see ). Follow-up Prostate Cancer Care Primary care practitioners provide an essential role for the continuity of patient care in all settings, both directly and through the coordination of care with other health care professionals. This reduces the fragmentation of care, improves patient safety, and enhances the overall quality of patient care. PSA Testing for Surveillance of Recurrent Disease In the absence of specific evidence to guide prostate-specific antigen (PSA) testing

2020 Clinical Practice Guidelines and Protocols in British Columbia

8. Prostate Cancer Part 1: Diagnosis and Referral in Primary Care

Cancer Tips, Advice, and Support – Prostate Centre Canada – Canadian Cancer Society – Diagnostic Code: 185 (malignant neoplasm of prostate) Abbreviations CCO - Cancer Care Ontario DRE - digital rectal exam ERSPC - European Randomized Study of Screening for Prostate Cancer LUTS - lower urinary tract symptoms PSA - prostate specific antigen This guideline is based on scientific evidence current as of November 2017 (refer to Methodology ). The guideline was developed by the BC Cancer Primary Care (...) the age of 60 when they are diagnosed and most men will survive their prostate cancer. It is estimated that 1 in 29 men who are diagnosed with prostate cancer would be expected to die of the disease. The following risk factors are associated with an increased risk of prostate cancer and should be considered when assessing men who present with symptoms or with questions about testing: Men of African descent. Family history of prostate cancer (paternal side; first-degree relatives (i.e., father

2020 Clinical Practice Guidelines and Protocols in British Columbia

9. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) ):3042-3050. doi: 10.1200/JCO.20.00315. Epub 2020 Jul 24. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Memorial Sloan Kettering Cancer Center, New York, NY. 2 Department of Biostatistics and Bioinformatics, Duke University, Durham, NC. 3 The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital

2020 EvidenceUpdates

10. Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. (Abstract)

Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer. Robotic-assisted laparoscopic prostatectomy (RALP) is widely used to surgically treat clinically localized prostate cancer. It is typically performed using an approach (standard RALP) that mimics open retropubic prostatectomy by dissecting the so-called space of Retzius anterior to the bladder. An alternative, Retzius-sparing (or posterior approach) RALP (RS (...) , of whom 502 completed the trials. Mean age of participants was 64.6 years and mean prostate-specific antigen was 6.9 ng/mL. About 54.2% of participants had cT1c disease, 38.6% had cT2a-b disease, and 7.1 % had cT2c disease. Primary outcomes RS-RALP probably improves continence within one week after catheter removal (risk ratio (RR) 1.74, 95% confidence interval (CI) 1.41 to 2.14; I2 = 0%; studies = 4; participants = 410; moderate-certainty evidence). Assuming 335 per 1000 men undergoing standard RALP

2020 Cochrane

11. Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG

Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG Metastatic castration-naive and castration-sensitive prostate cancer: CUA/CUOG To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2020 Canadian Urological Association

12. Managing prostate cancer during COVID-19 : CUOG/CUA

Managing prostate cancer during COVID-19 : CUOG/CUA Flipbook To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2020 Canadian Urological Association

13. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline - American Urological Association advertisement Toggle navigation About Us AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL (...) independently of androgen signaling resulting in CRPC. With a greater understanding of tumor biology, there is hope for continued development of innovative treatment options that further improve survival for men with CRPC. Non-metastatic castration-resistant prostate cancer Men with a rising PSA but no visible metastatic disease on conventional imaging despite medical or surgical castration represent a uniquely distinct disease state. The advent of improved imaging including next generation positron

2020 American Urological Association

14. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT (Full text)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} At 10-year median follow-up, there was no difference in disease-specific mortality between active monitoring, radical prostatectomy and radical radiotherapy treatments, which caused different side-effect profiles. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & . Freddie C Hamdy 1

2020 NIHR HTA programme PubMed abstract

15. Prostate cancer: NCCP advice for Medical Professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak

Prostate cancer: NCCP advice for Medical Professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) outbreak Version: 2 Department: NCCP Radiation Oncology Working Group Update date: 30/06/2020 Code: RO_COVID19_7 Page 1 of 3 NCCP advice for medical professionals on the management of patients undergoing Prostate Cancer Radiotherapy in response to the current novel coronavirus (COVID-19) pandemic This document (...) ) - https://www.gov.ie/en/campaigns/c36c85-covid-19- coronavirus/ ? Ireland’s National Action Plan in response to COVID-19 (Coronavirus) - https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/ 2 Purpose The purpose of this guidance document is to provide guidance to medical professionals on the management of patients undergoing Prostate Cancer Radiotherapy during the COVID-19 pandemic. In general prostate cancers are either low risk and delaying treatment does not impact outcomes or patients

2020 Health Service Executive (Ireland) - Clinical Guidelines

16. NCCP guidance for Medical Professionals on the management of patients with Prostate Cancer in response to the current novel coronavirus (COVID-19) outbreak

NCCP guidance for Medical Professionals on the management of patients with Prostate Cancer in response to the current novel coronavirus (COVID-19) outbreak Version: 4 Department: Prostate Guideline Development Group/Leads Group Update date: 11/06/2020 Revision date: Page 1 of 4 NCCP guidance for Medical Professionals on the management of patients with Prostate Cancer in response to the current novel coronavirus (COVID-19) pandemic This document relates to patients who do not have COVID-19 (...) - coronavirus/ ? Ireland’s National Action Plan in response to COVID-19 (Coronavirus) - https://www.gov.ie/en/campaigns/c36c85-covid-19-coronavirus/ Version: 4 Department: Prostate Guideline Development Group/Leads Group Update date: 11/06/2020 Revision date: Page 2 of 4 2 Purpose The purpose of this guidance document is to provide guidance to medical professionals on the management of patients referred to urology clinics, patients awaiting biopsy tests and patients diagnosed with prostate cancer during

2020 Health Service Executive (Ireland) - Clinical Guidelines

17. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials

Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials - PubMed This site needs JavaScript to work properly. Please enable (...) Actions . 2020 Jun 27;S0302-2838(20)30429-2. doi: 10.1016/j.eururo.2020.06.002. Online ahead of print. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials , , , , , , , , , Affiliations Expand Affiliations 1 Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; The National Center for Diabetes

2020 EvidenceUpdates

18. Prostate cancer screening with the PSA test

screening 24 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - 1 Background Prostate cancer is a malignant change in the prostate; as it progresses, it can infiltrate directly adjacent tissue (seminal vesicle, urinary bladder, large intestine) and can form distant metastases. As measured by the number of new cases, prostate cancer is the most common tumour disease in men in Germany, making up 23.0% of all cancer cases. For 2016, the Robert Koch Institute estimated that about (...) 58 780 men received an initial diagnosis of prostate cancer [1]. Age is considered the most important risk factor for the development of prostate cancer [1, 2]. At a median age of onset of 72 years, prostate cancer occurs predominantly in advanced age; it is rarely found before the 45 th to 50 th year of life [1]. Every year, about 14 000 men in Germany die of the consequences of prostate cancer [1]. The prognosis of the disease decisively depends on the tumour stage as well as tumour typing

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials

Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions . 2020 May 12;JCO1903217. doi: 10.1200/JCO.19.03217. Online ahead of print. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials

2020 EvidenceUpdates

20. Clinical Practice Guidelines – Prostate Cancer

Clinical Practice Guidelines – Prostate Cancer Prostate Cancer | ESMO Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. MINIMAL Requirements: , , , , , Search Clinical Practice Guidelines – Prostate Cancer Published in 2020 – Ann Oncol (2020) Authors: C. Parker, E. Castro, K. Fizazi, A. Heidenreich, P. Ost, G. Procopio, B. Tombal & S. Gillessen Prostate cancer is reported as the second most common cancer in men. The updated (...) ESMO Clinical Practice Guidelines on prostate cancer provide information on the current management of prostate cancer including recommendations for screening and diagnosis, along with stage-matched therapeutic strategies. Related items Read full article Legal Useful links Subscribe to ESMO newsletters Receive information and updates on ESMO’s scientific and educational resources, events, members activities. To sign up for ESMO newsletters, and select the newsletters you’d like to receive. ESMO

2020 European Society for Medical Oncology